Trastuzumab and Pertuzumab Suspected Therapy-Induced Ocular Toxicity in Patient Living with HER2-Positive Advanced Breast Cancer

Introduction

Trastuzumab and pertuzumab, in combination with chemotherapy, are first-line anti-human epidermal growth factor 2 (HER2) therapies in the treatment of HER2-positive metastatic breast cancer. Although these therapies have been shown to improve the overall survival of patients, they can also be associated with adverse events; ocular toxicities have not been well-documented.